期刊文献+

原发性醛固酮增多症大鼠模型的建立

Establishment of a rat model of primary hyperaldosteronism
原文传递
导出
摘要 目的建立原发性醛固酮增多症大鼠模型。方法利用微量渗透泵这一给药系统,将其埋植在大鼠背部皮下建立醛固酮增多症模型。其中模型组经微量渗透泵持续释放醛固酮(1μg/h,4周);拮抗组除给予等量醛固酮外,每日行螺内酯灌胃(每日100mg/kg);对照组仅泵空白溶剂。尾套法检测大鼠血压,测定血钾、钠、醛固酮浓度及血浆肾素活性。4周末使用代谢笼收集大鼠24h尿,测定尿钾、尿钠含量。结果成功建立醛固酮增多症大鼠模型,模型组大鼠2周后血压明显升高,血钾下降,呈现低肾素、高醛固酮特征,24h尿钾排出量增多,与对照组和拮抗组比较差异有统计学意义(P〈0.01)。结论借助微量渗透泵这一载体,可成功建立醛固酮增多症动物模型,方法简单,成功率较高。 Objective To introduce a method for establishing a rat model of primary hyperaldosteronism. Methods An osmotic minipump as a drug delivery system was implanted subcutaneously on the back of a rat for 4 weeks. Sprague-Dawley rats were randomly divided into three groups ( n = 8 per group ) : model group receiving aldosterone ( 1 μg/h, subcutaneously), antagonistic group receiving spirono- lactone ( 100 mg/kg · d^-1 ,gastric gavage) plus the equal doses of aldosterone ,control group receiving vehicle (subcutaneously). Systolic blood pressure was measured by the tail-cuff method weekly. All rats were placed in metabolism cage for collecting the 24 h urine and measuring the content of Na ^+ ,K ^+ 4 weeks later. When rats were killed at the end of the experiment, blood was collected by puncturing inferior vena cava. Then serum Na^+ ,K^+ ,aldosterone and PRA were measured. Results The hyperaldosteronism models were successfully established. In model group, the systolic blood pressure was markedly elevated 2 weeks later, serum levels of K ~ and PRA were decreased, and plasma aldosterone level and 24 h K^+ content in urine were increased. The differences were statistically significant compared with the other two groups ( P 〈 0.01 ). Conclusion The rat model of hyperaldosteronism can be successfully established with an osmotic minipump. The method is characteristic of simplicity, high success and no complications. It offers an effective tool for studying the primary aldosteronism.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2009年第6期791-793,共3页 Chinese Journal of Experimental Surgery
基金 国家杰出青年科学基金资助项目(30725040)
关键词 醛固酮增多症 模型 动物 大鼠 Hyperaldosteronism Models,animal Rats
  • 相关文献

参考文献12

  • 1Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism : an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol,2003 ,285 :813-821.
  • 2Brilla CG,Pick R,Tan LB,et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res, 1990,67:1355-1364.
  • 3Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension, 1994,23:587-592.
  • 4Weber KT, Sun Y, Campbell SE, et al. Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids, 1995,60 : 125-132.
  • 5Nakamura Y, Suzuki S, Suzuki T, et al. MDM2 : a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am J Pathol,2006,169:362-371.
  • 6Ishizawa K, Izawa Y, Ito H, et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension ,2005,46 : 1046-1052.
  • 7Sugiyama T, Yoshimoto T, Hirono Y, et al. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun ,2005,336 : 163-167.
  • 8李朝晖,谢晓华,刘丽,常连庆,陈雯,邓朝阳.外源性醛固酮负性调控大鼠血浆神经肽Y的相关信号通路[J].心脏杂志,2005,17(2):109-110. 被引量:2
  • 9陈雯,谢晓华,常连庆,孙愚,张颖,牟丽华,刘宁,刘秀华.醛固酮上调大鼠组织钙调神经磷酸酶活性及抑制血浆一氧化氮水平[J].高血压杂志,2005,13(11):721-724. 被引量:4
  • 10Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart :role of oxidative stress. Am J Pathol,2002,161 : 1773-1781.

二级参考文献15

  • 1陈雯,谢晓华,常连庆,孙愚,李朝晖,卢文宁,李晓玲,刘宁,刘秀华.醛固酮介导的肾性高血压相关靶器官组织钙调神经磷酸酶活性的变化[J].中国现代医学杂志,2004,14(17):58-61. 被引量:5
  • 2Onuoha GN, Nicholls DP, Alpar EK, et al. Regulatory peptides in the heart and major vessels of man and mammals [J]. Neuropeptides,1999, 33 (2): 165 -172.
  • 3Takeda Y, Yoneda T, Demura M, et al. Cardiac aldosterone production in genetically hypertentive rats [J]. Hypertention,2000,36: 495-500
  • 4Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension and cardiac fibrosis[J]. J Clin Invest, 1994,93: 2578-2583.
  • 5Young M, Head G, Funder JW, et al. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states[J]. Am J Physiol, 1995,269: E657-662.
  • 6Takeda Y, Yoneda T, Demura M, et al. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy [J].Circulation, 2002,105: 677-679.
  • 7Navarro AJ, Hemandez PO, Lopez OS, et al. CsA and FK506 up-regulate eNOS expression:role of reactive oxygen species and AP-1[J]. Kidney Int Suppl,1998,68:S20-24.
  • 8Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy[J]. Cell, 1998,93:215-228.
  • 9Bocs V, Abbott KL, Wang XF, et al. The cyclosporin A-sensitive nuclear factor of activated T cells(NFAT) proteins are expressed in vascular smooth muscle cells[J]. J Bio Chem, 1998,273:19664-19671.
  • 10Shibasaki F, Mcken F. Calcineurin function in Ca2+ activated cell death in mammalian cells[J]. J Cell Biol, 1995,131:735-743.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部